BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

929 related articles for article (PubMed ID: 18691743)

  • 21. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
    Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT
    Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
    Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
    Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes.
    Del Rosso A; Cinelli M; Guiducci S; Pignone A; Fibbi G; Margheri F; Gabrielli A; Giacomelli R; Coppini A; Del Rosso M; Matucci Cerinic M
    Rheumatology (Oxford); 2005 Oct; 44(10):1255-62. PubMed ID: 15998634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
    Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
    Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urokinase plasminogen activator (uPA) and its receptor (uPAR) in gestational tissues; Measurements and clinical implications.
    Uszyński M; Perlik M; Uszyński W; Zekanowska E
    Eur J Obstet Gynecol Reprod Biol; 2004 May; 114(1):54-8. PubMed ID: 15099871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The urokinase system in patients with intermittent and persistent allergic rhinitis.
    Kasperska-Zajac A; Brzoza Z; Rogala B
    Blood Coagul Fibrinolysis; 2008 Oct; 19(7):685-8. PubMed ID: 18832910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
    Bhuvarahamurthy V; Schroeder J; Kristiansen G; Roigas J; Denkert C; Johannsen M; Lein M; Loening SA; Schnorr D; Jung K; Staack A
    Oncol Rep; 2005 Sep; 14(3):777-82. PubMed ID: 16077991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
    Warnecke-Eberz U; Prenzel KL; Baldus SE; Metzger R; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
    Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The plasma levels of transforming growth factor beta1 and the protein expressions of alpha-SMA, urokinase plasminogen activator and plasminogen activator inhibitor-1 in liver of patients with different grades of hepatic fibrosis].
    Wu XR; Lv MH; Wang Q; Shi SS; Guo WD
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):400-2. PubMed ID: 15268802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer].
    Chen WH; Wang C; Zhang YH; Yang YH; Zhan HY; Zhang LM
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3228-32. PubMed ID: 18399120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
    Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
    Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
    Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
    J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.
    Minoo P; Baker K; Baumhoer D; Terracciano L; Lugli A; Zlobec I
    Hum Pathol; 2010 Jan; 41(1):70-8. PubMed ID: 19740518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
    Strojan P; Budihna M; Smid L; Vrhovec I; Skrk J
    Anticancer Res; 2000; 20(5C):3975-81. PubMed ID: 11268487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urokinase receptor variants in tissue and body fluids.
    Høyer-Hansen G; Lund IK
    Adv Clin Chem; 2007; 44():65-102. PubMed ID: 17682340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
    Pavey SJ; Marsh NA; Ray MJ; Butler D; Dare AJ; Hawson GA
    Boll Soc Ital Biol Sper; 1996; 72(11-12):331-40. PubMed ID: 9178585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease.
    Sidenius N; Nebuloni M; Sala S; Zerbi P; Price RW; Gisslen M; Hagberg L; Vago L; Lazzarin A; Blasi F; Cinque P
    J Neuroimmunol; 2004 Dec; 157(1-2):133-9. PubMed ID: 15579290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.